Results 21 to 30 of about 52,780 (163)

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Blood, 2021
Introduction: Idecabtagene vicleucel (ide-cel, bb2121) is the first chimeric antigen receptor (CAR) T cell therapy approved for the treatment of relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an ...
N. Raje, N. Shah, S. Jagannath, J. Kaufman, D. Siegel, N. Munshi, J. Rosenblatt, Yi Lin, A. Jakubowiak, A. Timm, Ashish S. Yeri, N. Martin, T. Campbell, O. Finney, A. Truppel-Hartmann, F. Petrocca, J. Berdeja, M. Alsina   +17 more
semanticscholar   +1 more source

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.

American Journal of Respiratory and Critical Care Medicine, 2020
RATIONALE Vascular remodeling, including smooth muscle cell hypertrophy and proliferation, is the key pathological feature of pulmonary arterial hypertension (PAH).
Yuhu He, C. Zuo, Daile Jia, Peiyuan Bai, Deping Kong, Di Chen, Guizhu Liu, Juanjuan Li, Yuanyang Wang, Guilin Chen, Shuai Yan, Bing Xiao, Jian Zhang, Linjuan Piao, Yanli Li, Yi-Ni Deng, Bin Li, Philippe P Roux, K. Andreasson, R. Breyer, Yunchao Su, Jian Wang, Ankang Lyu, Yujun Shen, Ying Yu   +24 more
semanticscholar   +1 more source

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.

Blood Advances, 2021
Antibody-drug conjugates directed against tumor-specific targets have allowed targeted delivery of highly potent chemotherapy to malignant cells while sparing normal cells.
Eileen Y. Hu, Priscilla Do, S. Goswami, J. Nunes, Chi-Ling Chiang, Sara Elgamal, Ann Ventura, C. Cheney, K. Zapolnik, E. Williams, R. Mani, F. Frissora, X. Mo, L. Waldmeier, R. Beerli, Haiyong Peng, C. Rader, M. Long, U. Grawunder, J. Byrd, N. Muthusamy   +20 more
semanticscholar   +1 more source

Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort.

European Heart Journal, 2020
AIMS Physical activity reduces cardiovascular disease burden and mortality, although its relationship with cardiac arrhythmias is less certain. The aim of this study was to assess the association between self-reported physical activity and atrial ...
A. Elliott, D. Linz, R. Mishima, K. Kadhim, C. Gallagher, M. Middeldorp, Christian V Verdicchio, J. Hendriks, D. Lau, A. La Gerche, P. Sanders   +10 more
semanticscholar   +1 more source

DP1 Activation Reverses Age-Related Hypertension Via NEDD4L-Mediated T-Bet Degradation in T Cells

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Blood pressure often rises with aging, but exact mechanisms are still not completely understood.
Deping Kong, Qiangyou Wan, Juanjuan Li, Shengkai Zuo, Guizhu Liu, Qian Liu, Chenchen Wang, Peiyuan Bai, S. Duan, Bin Zhou, F. Gounari, Ankang Lyu, M. Lazarus, R. Breyer, Ying Yu   +14 more
semanticscholar   +1 more source

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center

Cancers, 2021
Simple Summary Age is one of many prognostic factors for overall survival in patients with skeletal osteosarcoma. This retrospective study provides an overview of survival in patients with high-grade osteosarcoma in different age groups.
R. Evenhuis, I. Acem, A. J. Rueten-Budde, D. S. Karis, M. Fiocco, Desirée M J Dorleijn, F. Speetjens, J. Anninga, H. Gelderblom, M. V. D. van de Sande   +9 more
semanticscholar   +1 more source

Application of Amberlite IRA 402 Resin Adsorption and Laccase Treatment for Acid Blue 113 Removal from Aqueous Media

Polymers, 2021
Despite Acid Blue 113 (AB 113)’s extensive use and negative environmental impact, very few studies have focused on its efficient and environmentally friendly removal.
N. Marin, I. Stanculescu
semanticscholar   +1 more source

A 2-Dose AERAS-402 Regimen Boosts CD8+ Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients

Frontiers in Immunology, 2021
Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-deficient
D. Sivakumaran, G. Blatner, Rasmus Bakken, D. Hokey, C. Ritz, S. Jenum, H. Grewal   +6 more
semanticscholar   +1 more source

Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives

Drugs, 2017
Prostaglandin D2 (PGD2) released by degranulating mast cells is believed to play a key role in orchestrating mechanisms of inflammation in allergies and asthma.
M. Kupczyk, P. Kuna
semanticscholar   +1 more source

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

, 2020
Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B-cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed refractory multiple myeloma (RRMM).
M. Alsina, N. Shah, N. Raje, S. Jagannath, D. Madduri, J. Kaufman, D. Siegel, N. Munshi, J. Rosenblatt, Yi Lin, A. Jakubowiak, J. Jasielec, A. Timm, Ashley Turka, Pingping Mao, N. Martin, T. Campbell, K. Hege, H. Bitter, F. Petrocca, J. Berdeja   +20 more
semanticscholar   +1 more source